Refractory IHCA and OHCA Treated With ECMO

Refractory In and Out of Hospital Cardiac Arrest Treated With Extracorporeal Membrane Oxygenation. Observational, Single Centre, Prospective Study.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01298050

Acronym

SEAC

Enrollment

Registered

2011-02-17

Start date

2011-07-31

Completion date

2013-07-31

Last updated

2011-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest

Brief summary

Extracorporeal membrane oxygenation (ECMO) support has been suggested to improve the survival rate in patients with refractory cardiac arrest (CA). Recent studies have also highlighted the potential early application of this method in improving the prognosis of prolonged cardiac arrest both for in hospital CA (INHCA) and out of hospital CA (OHCA). The rationale for use of ECMO in these patients is to optimize early perfusion of vital organs, curing the cause of CA and waiting for the recovery of the injured myocardium. The investigators have created a flow-chart to decide which patients are eligible. The aims of this study are to evaluate if, with this flow-chart, the investigators are able to detect which patients have more probability of survival.

Interventions

PROCEDUREECMO

Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Adults 18-75 years old * In and out of hospital Witnessed Cardiac Arrest * No-flow time \< 5 min. or VF,VT,TP as rhythm of presentation * Low-flow time \< 45 min. * End Tidal CO2 \> 10 after 20 min.of CPR

Exclusion criteria

* Comorbidities such: * Terminal Malignancy * Aortic Dissection * Severe Cardiac Failure without transplant indication * Severe Aortic Valve Failure * Known Severe Peripheral arteriopathy

Design outcomes

Primary

Measure	Time frame
28 days survival	28 days

Secondary

Measure	Time frame	Description
Neurologic recovery	28 days	Neurologic recovery defined as minimal neurologic impairment according to the Glasgow-Pittsburgh cerebral performance categories score ≤ 2.
Cardiac recovery	28 days	Measured by echocardiography
Six months survival with minimal neurologic impairment	180 days	survival with minimal neurologic impairment according to the Glasgow-Pittsburgh cerebral performance categories score ≤ 2.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026